CervoMed Inc. will present at investor conferences in September regarding its treatments for age-related neurologic disorders.
Quiver AI Summary
CervoMed Inc. has announced its participation in two investor conferences in September 2025, focusing on its development of treatments for age-related neurologic disorders. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and will also engage in 1x1 investor meetings at Morgan Stanley’s 23rd Annual Global Healthcare Conference from September 8-10, 2025. CervoMed is currently advancing its investigational drug neflamapimod, aimed at treating neurodegenerative diseases like Dementia with Lewy Bodies (DLB). Neflamapimod is being evaluated in a Phase 2b trial, targeting synaptic dysfunction associated with these disorders.
Potential Positives
- Company management's participation in multiple investor conferences enhances visibility and engagement with potential investors.
- The announcement highlights the ongoing clinical development of neflamapimod, indicating progress in their efforts to address age-related neurologic disorders.
- Public communication through webcasts allows for broader outreach and transparency, potentially attracting interest in the company's initiatives.
Potential Negatives
- Company is still in clinical stage, indicating that products are not yet commercially available or proven, which may cause investor concern about timelines and viability.
- Neflamapimod is only in a Phase 2b trial; potential for long approval timelines and uncertainty about effectiveness may weigh on investor confidence.
- Participation in investor conferences may suggest the company is seeking additional funding or trying to bolster investor interest amidst potential challenges in clinical development.
FAQ
What is CervoMed Inc. focused on developing?
CervoMed Inc. is focused on developing treatments for age-related neurologic disorders.
When will CervoMed participate in investor conferences?
CervoMed will participate in investor conferences during September 2025, specifically on September 8-10.
What is the presentation time for the H.C. Wainwright conference?
The presentation at the H.C. Wainwright conference is scheduled for September 8, 2025, from 2:00 to 2:30 PM ET.
Where can I access the CervoMed investor webcasts?
The webcasts of the conferences can be accessed in the Investor section of the CervoMed website.
What is neflamapimod and its significance?
Neflamapimod is an investigational drug aimed at treating synaptic dysfunction in dementias like DLB.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRVO Insider Trading Activity
$CRVO insiders have traded $CRVO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CRVO stock by insiders over the last 6 months:
- WILLIAM ROBERT ELDER (CFO, GC & Secretary) purchased 4,233 shares for an estimated $35,811
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRVO Hedge Fund Activity
We have seen 16 institutional investors add shares of $CRVO stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 244,574 shares (-70.2%) from their portfolio in Q2 2025, for an estimated $1,537,147
- MORGAN STANLEY added 238,233 shares (+173.8%) to their portfolio in Q2 2025, for an estimated $1,497,294
- STATE STREET CORP removed 93,129 shares (-83.1%) from their portfolio in Q2 2025, for an estimated $585,315
- MILLENNIUM MANAGEMENT LLC added 76,080 shares (+inf%) to their portfolio in Q2 2025, for an estimated $478,162
- WOODLINE PARTNERS LP removed 74,852 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $684,895
- JANE STREET GROUP, LLC added 65,939 shares (+inf%) to their portfolio in Q2 2025, for an estimated $414,426
- GEODE CAPITAL MANAGEMENT, LLC removed 62,225 shares (-53.4%) from their portfolio in Q2 2025, for an estimated $391,084
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRVO Analyst Ratings
Wall Street analysts have issued reports on $CRVO in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Roth Capital issued a "Buy" rating on 08/12/2025
- D. Boral Capital issued a "Buy" rating on 08/11/2025
- Chardan Capital issued a "Buy" rating on 08/11/2025
- Canaccord Genuity issued a "Buy" rating on 07/29/2025
- Roth MKM issued a "Buy" rating on 03/18/2025
- Jones Trading issued a "Buy" rating on 03/13/2025
To track analyst ratings and price targets for $CRVO, check out Quiver Quantitative's $CRVO forecast page.
$CRVO Price Targets
Multiple analysts have issued price targets for $CRVO recently. We have seen 6 analysts offer price targets for $CRVO in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $31.0 on 08/18/2025
- Boobalan Pachaiyappan from Roth Capital set a target price of $16.0 on 08/12/2025
- Daniil Gataulin from Chardan Capital set a target price of $15.0 on 08/11/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $27.0 on 07/29/2025
- Boobalan Pachaiyappan from Roth MKM set a target price of $20.0 on 03/18/2025
- Soumit Roy from Jones Trading set a target price of $15.0 on 03/13/2025
Full Release
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:
H.C. Wainwright 27
th
Annual Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Presentation Date: Monday, September 8, 2025
Presentation Time: 2:00 – 2:30 PM ET
Webcast:
https://journey.ct.events/view/b01e16a4-43fd-41b8-b4c0-2815213f7950
Morgan Stanley’s 23
rd
Annual Global Healthcare Conference
Format: 1x1 Investor Meetings
Conference Dates: September 8-10, 2025
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ .
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
[email protected]
617-430-7579
